This inventor holds 12 USPTO granted patents and 17 published patent applications and 1 EPO patent. Top assignee: Kymab Limited. Active years: 2017-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2026
Title: The Innovative Journey of Volker Germaschewski in Cambridge, GB
Introduction
Volker Germaschewski is a notable inventor based in Cambridge, GB, renowned for his contributions to the field of biotechnology. With an impressive portfolio of 10 patents, he has made significant strides in the development of innovative therapeutic solutions. His work primarily focuses on novel antibodies that play a crucial role in immunotherapy.
Latest Patents
Germaschewski's latest patents include pioneering research on anti-PD-L1 antibodies. These groundbreaking inventions pertain to bispecific antibodies that possess a domain specifically targeting PD-L1, and encompass immunocytokines that fuse an anti-PD-L1 antibody to a cytokine such as IL-2. His patents also outline methods of treatment, various uses, and pharmaceutical compositions that incorporate these innovative antibodies, bispecific antibodies, and immunocytokines.
Career Highlights
Throughout his career, Germaschewski has demonstrated exceptional expertise in the biopharmaceutical sector. Currently, he is affiliated with Kymab Limited, a leading company in the field that focuses on the development of antibody therapies. His commitment to advancing medical science is evident through his numerous patents and the knowledge he brings to his research.
Collaborations
In addition to his individual achievements, Germaschewski collaborates with several esteemed colleagues, including Jamie Iain Campbell and Ian Kirby. This collaborative approach enhances the dynamic nature of his research, facilitating the exploration of diverse scientific perspectives and techniques.
Conclusion
Volker Germaschewski stands out as a key figure in the biotechnology arena. His inventions, particularly in the realm of anti-PD-L1 antibodies, signify a leap forward in immunotherapy. As he continues his work with Kymab Limited, his role as an inventor not only shapes the future of therapeutic interventions but also helps to inspire the next generation of scientists and inventors in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile